Skip to main content
. 2018 Oct 11;10:1758835918804151. doi: 10.1177/1758835918804151

Figure 2.

Figure 2.

Ongoing phase III clinical trials combining durvalumab with tremelimumab in different NSCLC populations.

LA, locally advanced; OS, overall survival; PFS, progression-free survival; q2w, every 2 weeks; q4w, every 4 weeks; q12w, every 12 weeks; wt, wild type.